Your doctor would be the most informed person to answer a question like that.
Have you had further testing CT or MRI?
Have you received this as a diagnosis?
Your liver has cirrhosis by definition that is not considered good shape. You are still in relatively good health as you are still compensated that is a different thing from the health of your liver.
The prognosis of HCC patients is much poorer in the presence of PVTT; their overall survival is only 2-4 months with supportive care [7–8]. The worse prognosis of HCC patients with PVTT may reflect several factors, including larger tumors, more numerous tumors, poorer tumor grade, worse liver function and higher serum levels of alpha-fetoprotein. These factors likely conspire to explain the low liver function, tumor aggressiveness, low chemotherapy tolerance and high risk of complications related to portal hypertension that are often observed in HCC patients with PVTT
The available evidence suggests that hepatic resection may be appropriate first-line therapy for many HCC patients with Vp1-3 PVTT and preserved liver function, which would provide them access to a potentially curative treatment. In contrast, no curative treatment is currently available for HCC with Vp4 PVTT. Resection-based combination therapies may also be effective for many patients with HCC and PVTT, as long as preserved liver function is adequate. Future research is needed to optimize the type, dosing and timing of neoadjuvant or adjuvant treatments administered with hepatectomy in different HCC patients with PVTT. Future studies should focus on optimizing patient selection criteria for various combination therapies in order to maximize the benefits of resection. For patients with unresectable HCC and PVTT, then TACE/TAC, radiotherapy, or radioembolization with yttrium-90 should be considered. Future recommendations for managing HCC with PVTT must be based on clear evidence from large, well-designed, randomized controlled trials.
Prognoses of patients with HCC and PVTT treated by hepatic resection
These results, together with systematic study of resection outcomes according to type of PVTT, argue for expanding official guidelines to recognize hepatic resection as a first-line option for selected patients with HCC and PVTT and preserved liver function. Analysis of 1021 patients in Japan with Vp3 or Vp4 PVTT who underwent resection showed a 5-year survival rate of 18.3%
Average follow-up for all HCC patients in this study was 20.4 months. Overall median survival of all 389 patients was 11 months from the date of diagnosis. The 1-year survival rate was 49%, after 3 years 19% of all patients were still alive
Immunotherapy for hepatocellular carcinoma: Current and future
Is Immunotherapy for liver cancer successful?
At last year's Liver Meeting, researchers reported that people treated with this regimen had a median overall survival of 22.8 months. The 12-month overall survival rate was 61% and the 24-month survival rate was 48%. Treatment with Opdivo and Yervoy was generally safe, though side effects were common.Apr 1, 2020
Systemic Treatment Options in Hepatocellular Carcinoma
Really good article citing different patient cases with differing amounts of liver disease.
From what I’m seeing is the preferred treatments for HCC if caught in early stages the preferred treatments are either removing the cancer tumors (resection) or liver transplant.
If the cancer is more advanced and operating is not an option that is when they will use immunotherapy type treatments to extend life this is referred to as palliative care while resection or transplant are considered curative.
Bottom line if you define success of systemic immunotherapies as increased life span:
“For advanced HCC, median survival now surpasses 2 years with the recent approval of multiple systemic therapies. The results of several ongoing phase 3 trials are eagerly awaited for potential new first‐line systemic treatments. While more progress is needed to further improve patient survival, the prognosis and available treatment options for HCC are only anticipated to improve.“
Any news what is going on with your situation? I have my next CG scan 4/28 to see if my two growths have grown or exhibit other signs of HCC